title: Three years of ibrutinib in CLL.
abstract: In this issue of Blood, Byrd et al provide an important update on the prolonged efficacy and the limited and reducing toxicity of the single-agent Bruton tyrosine kinase inhibitor ibrutinib in chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma patients who are followed for a median time of 3 years from start of treatment.
authors.affiliation: UNIVERSITY OF SOUTHAMPTON HOSPITAL TRUST.
authors.forename: Francesco
authors.identifier: http://orcid.org/0000-0002-2211-1831
authors.initials: F
authors.lastname: Forconi
mesh_terms: D005260:Female; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy*; D008297:Male; D011720:Pyrazoles / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*
chemical_list: D011720:Pyrazoles; D011743:Pyrimidines